Our Pricing

Why You're Not Losing Weight on Wegovy and What to Do Next

If you're not losing weight on Wegovy UK despite following your prescribed regimen, you're not alone—our clinical team at Cured Pharmacy sees this regularly and can help identify the underlying causes. Weight loss plateaus affect approximately 20-30% of patients on semaglutide therapy, but most cases can be resolved with targeted adjustments to dosing, lifestyle factors, or treatment approach. Understanding why Wegovy may not be delivering expected results is the first step toward achieving your weight management goals.

Common Reasons Why Wegovy Stops Working

Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces appetite and slows gastric emptying to promote weight loss [1]. In the STEP 1 clinical trial, participants achieved an average 14.9% body weight reduction over 68 weeks, but individual responses varied significantly—some patients experienced minimal results despite optimal adherence [1].

The most frequent cause of poor response is insufficient dose escalation. Wegovy follows a structured titration schedule starting at 0.25mg weekly and increasing gradually to the maintenance dose of 2.4mg. Patients who remain on lower doses due to side effect management or supply interruptions may not achieve therapeutic blood levels needed for significant weight loss [2].

Metabolic adaptation also plays a role. After initial weight loss, your body's basal metabolic rate naturally decreases—a phenomenon called adaptive thermogenesis. This means you burn fewer calories at rest than before starting treatment, which can slow or halt further weight reduction even while continuing Wegovy [3].

Dietary compensation is another critical factor our pharmacists frequently identify. GLP-1 medications reduce hunger signals, but some patients unconsciously increase calorie-dense food intake or liquid calories (smoothies, alcohol, sugary drinks) that bypass satiety mechanisms. Without concurrent dietary modification, the appetite-suppressing effects of Wegovy may be insufficient to create the caloric deficit needed for continued weight loss.

Medication Interactions That Reduce Wegovy Effectiveness

Certain medications can interfere with Wegovy's weight loss effects. Antipsychotics, some antidepressants (particularly mirtazapine and tricyclics), corticosteroids, and beta-blockers may promote weight gain or metabolic changes that counteract semaglutide's benefits. If you've started new medications since beginning Wegovy, discuss potential interactions with your UK prescriber—alternative formulations or treatment adjustments may be available.

How to Optimise Your Wegovy Treatment for Better Results

First, verify you've reached the full maintenance dose of 2.4mg weekly. Clinical data shows dose-dependent weight loss, with the 2.4mg dose producing significantly greater results than lower doses [1]. If side effects prevented dose escalation, your prescriber may recommend slower titration or anti-nausea strategies to help you reach therapeutic levels.

Protein intake optimisation is essential. Aim for 1.2-1.6g of protein per kilogram of ideal body weight daily—this preserves lean muscle mass during weight loss and increases satiety. Our clinical team often sees improved results when patients track protein intake alongside Wegovy treatment, as GLP-1 medications can inadvertently reduce protein consumption if appetite is severely suppressed.

Injection timing and technique matter more than many patients realise. Wegovy should be injected subcutaneously in the abdomen, thigh, or upper arm, rotating sites weekly to prevent lipohypertrophy (fatty lumps that reduce absorption). Some patients find injecting in the evening reduces next-day nausea, though timing doesn't significantly affect efficacy—consistency is what matters most.

Physical activity synergises with semaglutide's metabolic effects. While Wegovy works independently of exercise, combining treatment with 150-300 minutes of moderate-intensity activity weekly (as recommended by NICE guidelines) addresses the metabolic adaptation mentioned earlier and preserves muscle mass during weight loss [4]. Resistance training twice weekly is particularly beneficial for maintaining metabolic rate.

When to Reassess Your Treatment Timeline

If you've been on the full 2.4mg dose for 12-16 weeks without achieving at least 5% body weight reduction, it's appropriate to reassess your treatment plan with a UK prescriber. NICE guidance suggests this threshold as a marker of clinical response—patients not reaching it are unlikely to achieve significant long-term results with semaglutide alone and may benefit from alternative therapies or combination approaches.

Medical Conditions That May Prevent Weight Loss on Wegovy

Hypothyroidism affects approximately 2-3% of the UK population and can significantly impair weight loss efforts even on effective medications like Wegovy. Untreated or undertreated thyroid dysfunction slows metabolic rate and promotes fluid retention. If you're not losing weight on Wegovy despite good adherence, request thyroid function tests (TSH, free T4) from your GP—optimising thyroid hormone replacement can restore normal metabolic function.

Polycystic ovary syndrome (PCOS) creates insulin resistance and hormonal imbalances that make weight loss particularly challenging. While semaglutide improves insulin sensitivity and can help PCOS patients, the underlying metabolic dysfunction may limit results compared to patients without PCOS. Additional interventions like metformin or inositol supplementation may enhance Wegovy's effectiveness in this population [5].

Sleep apnoea and chronic sleep deprivation disrupt hunger hormones (ghrelin and leptin), increase cortisol, and impair glucose metabolism—all of which can counteract Wegovy's weight loss effects. Studies show that patients sleeping fewer than 6 hours nightly lose significantly less weight on GLP-1 therapy compared to those getting 7-9 hours. Addressing sleep quality through CPAP therapy (for apnoea) or sleep hygiene improvements may unlock better results.

Cushing's syndrome, though rare, causes excess cortisol production that promotes central obesity and insulin resistance. If you're experiencing weight gain or inability to lose weight alongside symptoms like easy bruising, muscle weakness, or facial rounding, discuss screening tests with your healthcare provider. Treating the underlying hormonal disorder is essential before weight loss medications can be effective.

Alternative Weight Loss Treatments When Wegovy Isn't Working

Mounjaro (tirzepatide) represents the next generation of weight loss therapy and may offer superior results if Wegovy hasn't met your expectations. As a dual GIP/GLP-1 receptor agonist, tirzepatide works through two complementary pathways rather than semaglutide's single mechanism. In head-to-head trials, tirzepatide produced approximately 5-7% greater weight loss than semaglutide at comparable timepoints [6].

The SURMOUNT-1 trial demonstrated that patients on the highest tirzepatide dose (15mg weekly) achieved an average 20.9% body weight reduction over 72 weeks—substantially higher than the 14.9% seen with Wegovy in STEP trials [6][1]. Importantly, a higher proportion of tirzepatide patients achieved clinically meaningful weight loss thresholds, suggesting it may benefit those who respond poorly to semaglutide.

Switching from Wegovy to Mounjaro requires careful transition planning. Most prescribers recommend starting tirzepatide at the 2.5mg dose one week after your last Wegovy injection, then following the standard titration schedule. This approach minimises gastrointestinal side effects while allowing the new medication to reach therapeutic levels. Our clinical team at Cured Pharmacy can facilitate this transition with appropriate prescriber oversight.

Combination approaches may also be considered for patients with partial Wegovy response. Some prescribers add orlistat (a lipase inhibitor that reduces fat absorption) or naltrexone/bupropion combinations to GLP-1 therapy, though evidence for these combinations remains limited. Any combination therapy requires careful monitoring and should only be undertaken with explicit prescriber guidance.

When to Consider Non-Medication Approaches

If you've tried multiple pharmacological options without success, referral to specialist weight management services may be appropriate. NHS Tier 3 programmes offer intensive behavioural support, dietetic input, and psychological therapy that addresses underlying eating patterns medications alone cannot resolve. For patients with BMI over 40 (or over 35 with comorbidities) who haven't responded to medical therapy, bariatric surgery consultation may be warranted—procedures like gastric sleeve or bypass produce average weight loss of 25-30% and can be more effective than any medication currently available.

Not Losing Weight on Wegovy: Troubleshooting Your Treatment Plan

Start with a detailed 7-day food and symptom diary. Track everything you consume (including drinks, condiments, and 'tastes' while cooking), injection timing, side effects, sleep hours, stress levels, and physical activity. This data helps identify hidden calorie sources, absorption issues, or lifestyle factors undermining your treatment. Our pharmacists review these diaries regularly with patients and frequently spot patterns the patient hadn't recognised.

Verify your Wegovy pens are stored and handled correctly. Semaglutide is a protein-based medication that degrades if exposed to temperatures above 30°C or frozen. Pens should be refrigerated before first use (2-8°C) and can be kept at room temperature (below 30°C) for up to 28 days after opening. Degraded medication loses potency—if your pens have been stored improperly, this could explain poor results.

Consider the timing of your weight loss expectations. Semaglutide's weight loss trajectory isn't linear—most patients experience rapid initial loss (weeks 0-16), followed by slower but continued reduction (weeks 16-52), then potential plateau (after 52 weeks). If you're in the slower phase, this may be normal treatment progression rather than treatment failure. Clinical trials showed continued gradual weight loss through 68 weeks, though the rate decreased substantially after the first 6 months [1].

Request prescriber review if you're experiencing persistent side effects. Severe nausea, vomiting, or gastrointestinal symptoms that prevent adequate nutrition can paradoxically impair weight loss by triggering metabolic stress responses and muscle catabolism. Your prescriber may recommend slower dose titration, anti-emetic co-prescription, or temporary dose reduction to improve tolerability while maintaining efficacy.

Getting Expert Support for Your Weight Loss Journey at Cured Pharmacy

At Cured Pharmacy, our UK-registered clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073) provides ongoing support throughout your weight loss treatment. We offer free online consultations under 3 minutes, transparent upfront pricing, and same-day prescription processing for eligible patients. All our medications are genuine UK-licensed products dispensed from our GPhC-registered premises (9012511).

If Wegovy isn't delivering the results you expected, we can arrange prescriber review to assess whether dose optimisation, treatment switching, or additional support would benefit you. Our clinical team has extensive experience managing complex weight loss cases and can identify factors that may not be apparent without specialist pharmacy input. We work collaboratively with your GP and other healthcare providers to ensure coordinated, evidence-based care.

We understand that weight loss treatment represents a significant investment—both financially and emotionally. That's why we're committed to lowest price guarantees across our weight loss range, with Wegovy available from £79.00 and discreet, rapid delivery to your door. Every prescription medication requires clinical assessment by a UK prescriber, but our streamlined process makes accessing expert care straightforward and convenient.

Whether you're troubleshooting your current Wegovy regimen or exploring alternatives, our team is here to provide the specialist pharmacy support you need. Contact us on (+44) 116 4646009 or complete an online consultation to discuss your treatment options with a qualified UK prescriber who can help you achieve your weight management goals.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
3. Rosenbaum, M., & Leibel, R. L. (2010). Adaptive thermogenesis in humans. International Journal of Obesity, 34(Suppl 1), S47–S55. https://doi.org/10.1038/ijo.2010.184
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189
5. Jensterle, M., Kravos, N. A., Ferjan, S., et al. (2015). Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocrine Disorders, 15, 21. https://doi.org/10.1186/s12902-015-0018-6
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence, lifestyle modifications, and underlying health conditions. Clinical trial data represents average outcomes and does not guarantee individual results.